Anemia License and Collaboration Agreement Sample Contracts
EX-10.12 32 d720189dex1012.htm EX-10.12 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities...Anemia License and Collaboration Agreement • May 5th, 2020
This Anemia License and Collaboration Agreement (“Agreement”) is made and entered into, effective as April 28, 2006 (“Effective Date”), by and between Astellas Pharma Inc., having a principal place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“Astellas”) and FibroGen, Inc., having a principal place of business at 225 Gateway Boulevard, South San Francisco, California 94080 U.S.A. (“FibroGen”).
Standard Contracts
Amendment to Anemia License and Collaboration AgreementAnemia License and Collaboration Agreement • September 24th, 2014 • Fibrogen Inc • Pharmaceutical preparations
This Amendment (the “Amendment”) to the Anemia License and Collaboration Agreement dated as of April 28, 2006, by and between Astellas Pharma Inc. and FibroGen, Inc. (the “Agreement”) shall be effective as of August 31, 2006.
AMENDMENT NO. 3 TO ANEMIA LICENSE AND COLLABORATION AGREEMENTAnemia License and Collaboration Agreement • September 24th, 2014 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 3 (the “Amendment”) to the Anemia License and Collaboration Agreement dated as of April 28, 2006, by and between Astellas Pharma Inc. (“Astellas”) and FibroGen, Inc. (“FibroGen”), as amended on August 31, 2006 and December 10, 2006 (the “Agreement”) is dated as of May 10, 2012 (the “Third Amendment Effective Date”). All capitalized terms not otherwise defined in this Amendment have the same meanings as set forth in the Agreement.
Amendment No. 2 to Anemia License and Collaboration AgreementAnemia License and Collaboration Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No 2. (the “Amendment”) to the Anemia License and Collaboration Agreement dated as of April 28, 2006, as amended on August 31, 2006, by and between Astellas Pharma Inc. and FibroGen, Inc. (the “Agreement”) shall be effective as of December 1, 2006.
Supplement to Anemia License and Collaboration AgreementAnemia License and Collaboration Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
This Supplement (this “Supplement”) to the Anemia License and Collaboration Agreement dated as of April 28, 2006, as amended, by and between Astellas Pharma Inc. and FibroGen, Inc. (the “Agreement”) is dated as of November 12, 2009, and shall be effective as of April 28, 2006. Astellas and FibroGen are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.” All capitalized terms not otherwise defined in this Supplement have the same meanings as set forth in the Agreement.